A phase I, multicentre, open-label, dose escalation study to determine the safety and preliminary efficacy of MBS8(1V270) administered intravenously to cancer patients with advanced solid tumours

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512294-26-00

Acronym

MBS8-101

Enrollment

103

Registered

2024-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Denmark, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026